These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 11141247)
21. Detection of resistant mutations in the reverse transcriptase of HIV-1-infected children. Palomares JC; Perea EJ; Terrero E; Torres MJ; García ML; Romero J; Alejo A Clin Microbiol Infect; 2000 May; 6(5):268-70. PubMed ID: 11168125 [No Abstract] [Full Text] [Related]
22. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307 [TBL] [Abstract][Full Text] [Related]
23. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367 [TBL] [Abstract][Full Text] [Related]
24. [Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy]. Gutiérrez F; Moltó J; Escolano C; Mora A; Pasquau F; Gregori J; Nogueira E Med Clin (Barc); 2000 Oct; 115(11):401-4. PubMed ID: 11093841 [TBL] [Abstract][Full Text] [Related]
25. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521 [TBL] [Abstract][Full Text] [Related]
26. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025 [TBL] [Abstract][Full Text] [Related]
27. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Lapadula G; Calabresi A; Castelnuovo F; Costarelli S; Quiros-Roldan E; Paraninfo G; Ceresoli F; Gargiulo F; Manca N; Carosi G; Torti C Antivir Ther; 2008; 13(4):601-5. PubMed ID: 18672539 [TBL] [Abstract][Full Text] [Related]
28. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. Ochoa de Echagüen A; Arnedo M; Xercavins M; Martinez E; Rosón B; Ribera E; Domingo P; González A; Riera M; Llibre JM; Gatell JM; Dalmau D; AIDS; 2005 Sep; 19(13):1385-91. PubMed ID: 16103769 [TBL] [Abstract][Full Text] [Related]
29. Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy. Pellegrin I; Segondy M; Garrigue I; Izopet J; Montes B; Pellegrin JL; Reynes J; Massip P; Puel J; Fleury H J Acquir Immune Defic Syndr; 2000 Dec; 25(5):465-6. PubMed ID: 11141248 [No Abstract] [Full Text] [Related]
30. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study. Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586 [TBL] [Abstract][Full Text] [Related]
34. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807 [TBL] [Abstract][Full Text] [Related]
35. Development of resistance mutations to nevirapine as part of triple-drug therapy in children. Seifert LL Pharmacotherapy; 2002 Jan; 22(1):113-7. PubMed ID: 11794422 [TBL] [Abstract][Full Text] [Related]
36. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Miller V; de Béthune MP; Kober A; Stürmer M; Hertogs K; Pauwels R; Stoffels P; Staszewski S Antimicrob Agents Chemother; 1998 Dec; 42(12):3123-9. PubMed ID: 9835502 [TBL] [Abstract][Full Text] [Related]